Inclusion of procalcitonin in the emergency department sepsis diagnostic algorithm did not affect the timeliness of intravenous antibiotic administration to patients. However, this care reduced short-term mortality. In one study, the procalcitonin-controlled group had a lower mortality rate (21.1%) than the control group (23.7%, P=0.03). The average duration of antibiotic treatment was reduced from 10.4 to 9.3 days (P=0.001). Further analysis showed a reduction in the length of antibiotic therapy by 0.9 days (from 10.7 to 9.8 days) with daily procalcitonin monitoring versus standard care. Mortality within 28 days was 20.9% in the procalcitonin group versus 19.4% in standard care, which confirms non-inferiority. Procalcitonin helps to shorten the duration of antibiotic treatment in patients with sepsis and respiratory infections without increasing the risk. A decrease in procalcitonin of more than 80% within 72 hours has a high predictive value (around 90%) for excluding ICU mortality.